DaVita Inc. $DVA Shares Sold by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC decreased its position in shares of DaVita Inc. (NYSE:DVA) by 15.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,086 shares of the company’s stock after selling 761 shares during the period. Integrated Wealth Concepts LLC’s holdings in DaVita were worth $625,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of DVA. GAMMA Investing LLC increased its holdings in shares of DaVita by 14,695.8% in the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company’s stock valued at $35,919,000 after acquiring an additional 233,222 shares during the period. Doma Perpetual Capital Management LLC increased its stake in DaVita by 172.3% in the first quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock valued at $44,110,000 after purchasing an additional 182,476 shares during the period. Northern Trust Corp increased its stake in DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after purchasing an additional 149,858 shares during the period. Nuveen LLC acquired a new position in DaVita in the 1st quarter valued at about $20,218,000. Finally, Rovin Capital UT ADV acquired a new position in DaVita in the 1st quarter valued at about $18,442,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 0.1%

Shares of DVA stock opened at $133.08 on Friday. The business’s fifty day moving average price is $138.45 and its 200 day moving average price is $141.54. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The firm has a market capitalization of $9.52 billion, a PE ratio of 13.09, a P/E/G ratio of 0.95 and a beta of 1.13. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts’ consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the prior year, the company posted $2.00 earnings per share. DaVita’s quarterly revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, sell-side analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 2,351 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on DVA shares. Bank of America dropped their target price on DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a report on Wednesday. Truist Financial set a $148.00 price objective on shares of DaVita in a research note on Friday, August 8th. Barclays dropped their price objective on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th. Finally, Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $158.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.